Emerging Immunotargets in Metastatic Renal Cell Carcinoma.


Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable… (More)


Cite this paper

@article{Kucharczyk2016EmergingII, title={Emerging Immunotargets in Metastatic Renal Cell Carcinoma.}, author={John R Kucharczyk and Marc Ryan Matrana and Matteo Santoni and Francesco Massari and Marina Scarpelli and Liang Cheng and Antonio Lopez-Beltran and Stefano Cascinu and Rodolfo Montironi and Moch Holger}, journal={Current drug targets}, year={2016}, volume={17 7}, pages={771-6} }